Login to Your Account



New Sales Burst For HIV Compound?

Gilead Asks Viread Approval In U.S., Europe Against HBV

By Randall Osborne


Monday, October 15, 2007
Gilead Sciences Inc.'s bid to win marketing approvals for Viread against hepatitis B virus in the U.S. and Europe could mean upside for the compound - which sold $154.9 million in the third quarter as an HIV therapy - that's been overlooked so far by Wall Street, and investors are due for a full look at the data from a pair of supporting trials early next month. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription